MedTrace Logo

CD30 CAR-T Cells for Low Risk Relapsed Classical Hodgkin Lymphoma

NCT07575893 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-20

No results posted yet for this study

Summary

Patients with relapsed low-risk CD30 classical Hodgkin Lymphoma will have autologous CD30 CAR T-cell manufactured. Dose escalation will be used to determine the RP2D. Following lymphodepletion, CAR T-cell will be infused.

Conditions

  • Classical Hodgkin Lymphoma

Interventions

BIOLOGICAL

CD30+ CAR T-cells

patients with cHL with a good response following reinduction therapy will receive autologous CD30 CAR T-cells 1-14 days following lymphodepletion

DRUG

Bendamustin

Patients will receive 70 mg/m2/day × 3 days prior to CD30 CAR T-cells

DRUG

Fludarabine

Patients will received 30 mg/m2/day × 3 days prior to CD30 CAR T-cells.

Sponsors & Collaborators

Principal Investigators

  • Mitchell Cairo, MD · New York Medical College

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2031-12-01
Completion
2032-12-01
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07575893 on ClinicalTrials.gov